Navigation Links
Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
Date:1/4/2011

NATICK, Mass., Jan. 4, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today issued the following statement from Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, on an article that was published online today by the Journal of the American Medical Association.  The article reported on a study that found that about 20 percent of patients who received an implantable cardioverter defibrillator (ICD) did not meet evidence-based guidelines for receipt of one.

"Guidelines represent consensus from the scientific community that a given procedure or treatment is beneficial, useful and effective.  Boston Scientific is proud to have sponsored many of the clinical trials that provided the scientific foundation for the guidelines referenced in the JAMA article.

"However, it is important to place these results in their appropriate clinical context.  Sudden cardiac arrest (SCA) is the most common cause of death in the U.S.  About 460,000 Americans die each year from SCA; that is more than lung cancer, breast cancer and HIV-related diseases combined.  Currently, more than a million patients are eligible for an ICD, but only a small percentage of patients actually receive the life-saving device.  In fact, previous studies show that ICDs are used in only 20-40 percent of indicated patients in the U.S.

"Dr. Sana Al-Khatib has made important contributions to addressing the under-utilization of device therapies for the prevention of SCA.  She played a key role in organizing the Sudden Cardiac Arrest Thought Leadership Alliance, a think tank on the issue that met in December 2009.  That meeting led to a recent publication on the issue: "Addressing disparities in sudden cardiac arrest care and the under-utilization of effective therapies."  Its major conclusion was: "Despite overwhelming clinical trial evidence, expert opinion, national guidelines, and a vast array of educational conferences, evidence-based, life-prolonging drug and device therapies continue to be under-utilized, with significant disparities in SCA care and use of ICDs in vulnerable populations, including blacks, women and the elderly."

"It is interesting to note that three of four cases cited in the JAMA article were outside the guidelines solely on the basis of timing, and that many of these patients would have qualified within a matter of weeks or months.

"ICD and cardiac resynchronization therapy defibrillator (CRT-D) therapies have been shown to be cost effective in the MADIT II, COMPANION and SCD-HeFT clinical trial patient populations.  In addition, long-term data from the MADIT II study showed that the life-saving benefits of ICD therapy were sustained at eight years (34 percent relative reduction in the risk of death).  In that trial, one life was saved for every eight patients who received an ICD.

"While ICDs are at times used outside the guidelines, the more fundamental problem is that on the whole, this life-saving therapy is under-utilized, rather than over-utilized."  

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com. CONTACT:

Paul Donovan508-650-8541 (office)508-667-5165 (mobile)Media RelationsBoston Scientific CorporationLarry Neumann508-650-8696 (office)Investor RelationsBoston Scientific CorporationSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific Corporation
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cannabis Science Files Preliminary 14c Information Statement, the Action is to Create a New Class of Common Stock and Issue Dividend
2. PhRMA Statement on Department of Homeland Security Efforts to Crack Down on Counterfeiting Crimes
3. Lilly Statement Regarding President Obamas Meeting With U.S. Business Leaders
4. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
5. ERT Files Shelf Registration Statement
6. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
7. Abbott Statement: Abbott Provides Support for Cholera Relief Efforts in Haiti
8. Media Statement From Amedisys on Dr. Steven H. Landers NEJM Commentary on the Future of Home Care
9. Statement of Ben Anderson, Esq., Regarding Denial of Wyeths En Banc Petition to Sixth Circuit Court of Appeals in Major Drug Regulation Pre-emption Case
10. Cellectis Publishes Its Financial Statement for the First Half of 2010
11. A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017  Abaxis, Inc. (NasdaqGS: ABAX ), ... and consumables for the medical and veterinary markets worldwide, ... results for the third quarter fiscal year 2017, ended ... p.m. ET on Thursday, January 26, 2017.  The Company ... year 2017 after the market closes on Thursday, January ...
(Date:1/19/2017)... -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the German ... Germany , has purchased a MRIdian ... Clinic Heidelberg as part of its initiative for MRI-based ... be headed by Medical Director and Professor Jürgen Debus, ... German Cancer Research Center (DKFZ), the Heidelberg Heavy Ion ...
(Date:1/19/2017)... England , January 19, 2017 ... and Otsuka in the Milner Therapeutics Consortium   ... scientists in Cambridge   ... (NYSE: PFE ) as a partner to ... the Consortium, which enables the efficient transfer of materials ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... ... panel system. , The Tranquility privacy panel system was designed to deliver ... Tranquility panels help reduce noise and provide the visual privacy required to maintain ...
(Date:1/19/2017)... ... ... Allegheny Health Network (AHN) officials today announced a bold new step to ... services in the greater Pittsburgh region. Starting January 23, patients who call AHN by ... same afternoon. , AHN is the first healthcare provider in the ...
(Date:1/19/2017)... GA (PRWEB) , ... January 19, 2017 , ... ... offers asset protection and financial planning services to communities throughout eastern Georgia, is ... fight against heart disease. , Heart disease kills more Americans every year than ...
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... locally owned insurance agency which serves Lawrenceville, New Jersey and the surrounding area, ... , Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease ...
(Date:1/19/2017)... ... 19, 2017 , ... Attorney Robert “RC” Pate , founder of The ... the Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric ... firsthand the effect of the critical funding gap for research into pediatric cancer research. ...
Breaking Medicine News(10 mins):